EMD Millipore, the Life Science division of Merck KGaA* of Germany, today introduced the first software application for visualizing GPCR (G-protein coupled receptors), as well as kinase activity. The new Data Analysis and Report Tool (DART™), which can be accessed through EMD Millipore’s Drug Discovery portal, creates an interactive map of target profiling assay results and enables drug researchers to make faster, more informed decisions.

“Lead profiling often requires sifting through hundreds or even thousands of data points to pinpoint targets for further optimization studies,” said Paul Wilhite, Senior Manager of eBusiness at EMD Millipore. “This new online tool provides a unique, information-rich interface so scientists can rapidly narrow their research and effectively collaborate with colleagues.”

The application projects each compound’s activity profile onto a map depicting clusters of target protein families. This map provides scientists with immediate graphical insight into cross-target interactions to help drive structure-activity relationship (SAR) studies. The application is fully customizable. Data limits, sizing, colors, and target subclasses can be adjusted in seconds, thereby turning numerical data into a graphical display that can highlight biologically significant conclusions. Additionally, selected target information is dynamically populated and includes the gene symbol and aliases; links to bioinformatics content and recent publications; as well as links to appropriate EMD Millipore products.

“DART is the latest in the continuum of bioinformatics tools that EMD Millipore has launched in the past two years,” said Siamak Baharloo, Director of eBusiness at EMD Millipore. “We will continue our efforts to provide our customers with high-value experiment design and data analysis tools that empower their research.”

Clients of EMD Millipore’s KinaseProfiler™ and GPCRProfiler® screening services can upload their data directly into the DART tool or enter other datasets manually to take advantage of the software’s analytical power and presentation-quality images. For more examples of DART map views and compound profiles, visit www.millipore.com/visualize2.

###

Source – http://www.prweb.com/releases/2010/08/prweb4423204.htm

• Aarkstore Enterprise -The Future of GPCRs in Drug Discovery: Novel technologies, leading companies,

The Future of GPCRs in Drug Discovery: Novel technologies, leading companies, and opportunities for target expansion G-protein coupled receptors (GPCRs) constitute the largest, most ubiquitous, and most versatile family of membrane receptors. They also constitute the class of targets that has been most effectively exploited by the pharmaceutical industry, with approximately 30% of all currently marketed

• Cellecta, Inc. Announces Launch of the Open Source DECIPHER Project to…

Cellecta, Inc., a provider of screening services for gene function analysis and therapeutic drug target discovery, announced the launch of the DECIPHER Project–an open source platform for genome-wide RNAi screening which offers reagents for running genetic knockdown screens, software tools for data analysis, and an open database of genetic knockdown screening results. Funded,

• Promega, MS Bioworks Collaboration Offers Advanced Mass Spectrometry…

Advancing biological research with high-quality mass spectrometry analysis is the basis of a new service offered by Promega and MS Bioworks (Ann Arbor, MI). Now scientists worldwide can access protein mass spectrometry expertise and leading-edge instrumentation with fast turnaround times. The service covers sample processing, high-quality analysis and transparent consulting from design to analysis. Promega and